Dai Xiufang, Yi Xianfu, Sun Zequn, Ruan Peng
Department of Breast Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Department of Emergency, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Biomed Rep. 2016 Apr;4(4):493-497. doi: 10.3892/br.2016.601. Epub 2016 Feb 16.
The aim of the present study was to assess the anti-hepatitis B virus (HBV) effect of L. () in the patients with chronic hepatitis B (CHB). A total of 60 randomly selected patients with CHB were recruited and divided into groups I and II. The patients in group I received a monotherapy of adefovir (ADV), and the patients in group II received a combination therapy of ADV and for >48 weeks. Intrahepatic (IH) HBV covalently closed circular DNA (cccDNA), serum HBV DNA, hepatitis B surface antigen (HBsAg), alanine aminotransferase levels and serum interferon-γ (IFN-γ) and transforming growth factor-β (TGF-β) levels were quantified during the test. Following the treatment, a significant reduction of the median IH cccDNA level was identified in group II (P=0.017), but not in group I (P=0.05, and P=0.01 between the 2 groups), and a significant reduction of log HBsAg was identified in groups I (P=0.012) and II (P<0.0001, and P=0.20 between the 2 groups). A significant increase of the median serum IFN-γ level was found in group II (P=0.0005), but not in group I (P=0.06, and P=0.004 between the 2 groups), and a significant reduction of the median TGF-β level was identified in groups I (P<0.0001) and II (P<0.0001, and P=0.002 between the 2 groups). A total of 24 patients in group I, and 27 patients in group II achieved a sustained virological response (P=0.0386), and 20 patients in group I and 24 in group II achieved hepatitis B e antigen seroclearance (P=0.0442). In conclusion, can effectively inhibit HBV transcription and replication in the patients by stimulating the release of the inflammatory cytokines, such as IFN-γ.
本研究的目的是评估[具体菌种名称未给出]对慢性乙型肝炎（CHB）患者的抗乙型肝炎病毒（HBV）作用。总共随机选取60例CHB患者，分为I组和II组。I组患者接受阿德福韦（ADV）单药治疗，II组患者接受ADV与[具体物质未给出]联合治疗超过48周。在试验期间对肝内（IH）HBV共价闭合环状DNA（cccDNA）、血清HBV DNA、乙型肝炎表面抗原（HBsAg）、丙氨酸转氨酶水平以及血清干扰素-γ（IFN-γ）和转化生长因子-β（TGF-β）水平进行定量分析。治疗后，II组中IH cccDNA水平中位数显著降低（P = 0.017），而I组未降低（P = 0.05，两组间P = 0.01），I组（P = 0.012）和II组（P < 0.0001，两组间P = 0.20）的log HBsAg均显著降低。II组中血清IFN-γ水平中位数显著升高（P = 0.0005），而I组未升高（P = 0.06，两组间P = 0.004），I组（P < 0.0001）和II组（P < 0.0001，两组间P = 0.002）的TGF-β水平中位数均显著降低。I组24例患者和II组27例患者实现了持续病毒学应答（P = 0.0386），I组20例患者和II组24例患者实现了乙型肝炎e抗原血清学清除（P = 0.0442）。总之，[具体物质未给出]可通过刺激IFN-γ等炎性细胞因子的释放，有效抑制患者体内HBV的转录和复制。
